Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine

Journal of Chemotherapy

Volumn 9, Issue 2, 1997, Pages 102-105

  Polyzos, A ^a   Tsavaris, N ^b   Veslemes, M ^c   Dardoufas, K ^d   Dosios, T ^b   Kosmas, C ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

cisplatin; etoposide; lung cancer; mitomycin; non small cell lung cancer; vinblastine

Indexed keywords

CISPLATIN; ETOPOSIDE; MITOMYCIN C; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE;

EID: 0031004963     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.2.102     Document Type: Article

References (17)

1. Bunn P Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16 (suppl. 6), 10-21.
2. Lin RJ. Chemotherapy outcomes in advanced non-small cell lung cancer. Semin Oncol 1993; 20: 296-301.
3. Folman RS, Rosman M. The role of chemotherapy in non-small cell lung cancer. The community perspective. Semin Oncol 1988; 15 (Suppl. 4): 16-21.
4. Mabel JA, Little AD. Therapeutic synergism in murine tumors for combination of cis-diamine-dichloroplatinum with VP-16-213 of BCNU. Proc Am Assoc Cancer Research 1979; 20: 230.
5. Klastersky J. Therapy with cisplatin and etoposide for non-small cell lung cancer. Semin Oncol 1986; 13 (Suppl 3): 104-114.
6. Dhingra HM, Valdivieso M, Carr DT, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1985; 3: 176-183.
7. Splinter T, Kok T, Kho S, et al. A multi-center phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small cell lung cancer. Semin Oncol 1986; 13 (suppl. 3): 97-103.
8. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva WHO Offset publication 1979, No 48.
9. Woolson RF. Comparison of two groups. T-test and rank-tests. In: Statistical methods for the analysis of biomedical data. New York, Wiley, 1987.
10. Ganz PA, Figlin RA, Haskell CM, La-soto N, Sian J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 1989; 63: 1271-1278.
11. Kaasa S, Lund E, Thorud E, Hatlevoll R, Host H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991; 67: 2443-2447.
12. Gralla RJ, Kris MG. Chemotherapy in non-small cell lung cancer. Results of recent trials. Semin Oncol 1988; (Suppl.) 15: 2-5.
13. Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O' Connell JP, Burke MT. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 1986; 70: 1091-1096.
14. Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation V. A randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985; 3: 72-79.
15. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party. Cancer 1982; 50: 2751-2756.
16. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4: 14-22.
17. Paccaguella A, Favaretto A, Brandes A, et al. Cisplatin, etoposide and ifosfamide in non-small-cell lung carcinoma. Cancer 1990; 65: 2631-2634.